General Neurology
Botulinum toxin treatment of neurologic disorders
Mar. 06, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Brain MRI of a patient with cerebral folate deficiency from age 2 to 12 years. T2-weighted images are shown at 2 years (column 1: A1-E1), 5 years (column 2: A2-E2), 7 years (column 3: A3-E3), 10 years (column 4: A4-E4), and 12 years (column 5: A5-E5). Sagittal (panel A) images show mild to moderate thinning of the corpus callosum (white arrowhead), as well as mild cerebellar atrophy (white arrow). In panels B1-3, C1-3, and D1-3, severe lack of myelin deposition and progressive cerebral atrophy are shown. In panels B4-5, C4-5, and D4-5, improvement in myelination is seen, but incomplete myelination is still present at age 12 years. Brain volume has improved at ages 10 and 12 years (B4-5, C4-5, and D4-5). In panel E, insufficient myelin deposition is shown in E1-2 in both the pons (white double-lined arrow) and cerebellum (white dashed arrow), with improvement in the pons at age 7 years (E3-5, white double-lined arrow) and significant improvement in the cerebellum at ages 10 and 12 years (E4-5, white double-lined arrows). Progressive cerebellar atrophy is evident between ages 2 and 7 years (E1-3), with improvement in subsequent MRIs done at ages 10 and 12 years (E4-5). (Source: Potic A, Perrier S, Radovic T, et al. Hypomyelination caused by a novel homozygous pathogenic variant in FOLR1: complete clinical and radiological recovery with oral folinic acid therapy and review of the literature. Orphanet J Rare Dis 2023;18[1]:187. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)